Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07303816 · ClinicalTrials.gov registry record · Phase 4
Statins to Prevent Cancer Associated Blood Clots
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 4,000
- Enrollment target
NCT07303816: Recruiting Phase 4 study, sponsored by Brigham and Women's Hospital.
NCT07303816 is a Phase 4 study that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 4,000 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (672% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07303816, a Phase 4 study, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 4,000 participants
- Enrollment target
Study Summary
Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20 mg daily for 12 months compared to placebo can safely prevent VTE in patients with newly diagnosed or recently relapsed cancer who are at increased thrombotic risk, are not planned to be anticoagulated, and who do not otherwise take statin therapy.
Primary Outcome
The primary endpoint of the trial is the time from taking the first dose of study medication after randomization (modified intention to treat, mITT) to the first confirmed occurrence of the primary VTE endpoint. The primary analysis will use a likelihood ratio test based on a proportional hazards model stratified by eligibility criteria (eligible due to KS criteria alone or eligible due to mKS criteria), and enrollng center to test the null hypothesis of no association between assignment to acti
Interventions
- DRUG Placebo Drug
- DRUG Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2026-06-11 |
| Est. Completion | 2032-03-31 |
| Phase | Phase 4 |
What NCT07303816 shows while recruiting
NCT07303816 is an interventional study that assigns participants to a tested intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (672% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo Drug is the first listed.
NCT07303816 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07303816 about?
NCT07303816 is a clinical study titled "Statins to Prevent Cancer Associated Blood Clots". Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to...
What is the current status of trial NCT07303816?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 4,000 participants. The study started on 2026-06-11. Estimated completion is 2032-03-31.
What interventions are being tested in trial NCT07303816?
The interventions under investigation include: Placebo Drug (DRUG), Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT07303816?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07303816's enrollment target sits among peer trials
4,000 20th of 2000 higher than 1,980 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI